D3 Bio Presents KRAS Pipeline at AACR
Analysis based on 7 articles · First reported Mar 20, 2026 · Last updated Mar 20, 2026
The market is positively impacted by D3 Bio's advancements in oncology therapeutics, particularly its KRAS pipeline. Successful presentations at the American Association for Cancer Research Annual Meeting 2026 could lead to increased investor confidence and potential future partnerships for D3 Bio.
D3 Bio, a global clinical-stage biotechnology company, announced that five abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California. Two of these abstracts were selected for oral presentations at the Clinical Trials Plenary Session and the Clinical Trials Mini-Symposium. The presentations will highlight data from D3 Bio's comprehensive pipeline targeting KRAS-driven cancers, including Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor; D3S-002, a selective ERK1/2 inhibitor; and D3S-003, a differentiated KRAS G12D inhibitor. George Chen, Founder, Chairman, and CEO of D3 Bio, expressed enthusiasm for sharing the company's scientific progress and commitment to advancing transformative therapies for patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard